Year
- 2025
- 2024
- 2023
- 2022
- 2021
- 2020
- 2019
- 2018
- 2017
- 2016
- 2015
- 2014
- 2013
- 2012
- 2011
- 2009
Type
- Journal
- Poster
- Presentation
Clear
September 28, 2025
Atebimetinib (IMM-1-104) + Modified Gemcitabine/Nab-Paclitaxel (mGnP) Shows Extraordinary Overall Survival (OS) and Favorable Tolerability in First-Line (1L) Metastatic PDAC: Updated Phase 2 Results
PanCAN Scientific Summit 2025 Encore Presentation
September 17, 2025
Deep Cyclic Inhibition of MEK: A Transformational Approach to Durable and Safe Combinations in Ras-Mutant Cancers
RAS-Targeted Drug Development Summit 2025
December 8, 2024
Potential anti-cachexia properties of novel dual-MEK inhibitor IMM-1-104
Sarcopenia, Cachexia, and Wasting Disorders Conference 2024
November 13, 2024
Phase 1 Interim Population PK/PD Modeling and Recommended Phase 2 Dose Exploration for IMM-1-104, A Novel Concept Oral Deep Cyclic Inhibitor of MEK
American Conference on Pharmacometrics 2024
September 16, 2024
Preliminary phase 1 safety and activity of IMM-1-104, an orally dosed universal RAS inhibitor that drives deep cyclic inhibition of the MAPK pathway at MEK, in patients with advanced unresectable or metastatic solid tumors
European Society for Medical Oncology Annual Conference 2024
April 9, 2024
Activity of IMM-1-104 alone or in combination with chemotherapy in RAS-altered pancreatic cancer models
American Association for Cancer Research Annual Meeting 2024
October 12, 2023
Deep Cyclic Inhibition of the MAPK pathway with IMM-6-415, alone and in combination with encorafenib, demonstrates anti-tumor activity and tolerability in RAF mutant tumors in vivo
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023
October 12, 2023
Predicting activity of IMM-1-104 as single agent and in combination for patients with RAS or RAF mutant tumors
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023
April 18, 2023
Humanized 3D tumor models that are mutually aligned with AACR GENIE patients predict IMM-1-104 activity in RAS-addicted tumors
American Association for Cancer Research Annual Meeting 2024
March 7, 2023
Pan-RAS IMM-1-104 activity in humanized 3D tumor models is independent of specific amino acid substitution
AACR Special Conference Targeting RAS 2023, Virtual Poster Presentation
March 5, 2023
Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS Activity
AACR Special Conference Targeting RAS 2023
November 10, 2022
Cyclic disruption of the mitogen-activated protein kinase (MAPK) pathway by the Dual MEK inhibitor, IMM-6-415, enhances PD-1 and CTLA-4 checkpoint blockade in RAS mutant tumors
Society for Immunotherapy of Cancer Annual Meeting 2022
May 26, 2022
Translational Modeling for Patients with RAS Mutant Tumors: Profiling the Dual-MEK Inhibitor IMM-1-104 in a Humanized 3D Assay
American Society of Clinical Oncology Annual Meeting 2022
May 26, 2022
Head-to-Head Comparison of the Dual-MEK Inhibitor IMM-1-104 versus Sotorasib or Adagrasib in KRAS Mutant Pancreatic Tumors
American Society of Clinical Oncology Annual Meeting 2022
January 6, 2022
Head-to-head comparison of the dual-MEK inhibitor IMM-1-104 versus binimetinib in NRAS mutant melanoma models
AACR Special Conference Targeting RAS 2022, Virtual Poster Presentation
January 3, 2022
Assessing reproducibility of inherited variants detected with short-read whole genome sequencing
Genome Biology
December 10, 2021
FDA-led consortium studies advance quality control of targeted next generation sequencing assays for precision oncology
Precision Cancer Medicine
November 17, 2021
Reporting guidelines for human microbiome research: the STORMS checklist
Nature Medicine
November 3, 2021
Advancing NGS quality control to enable measurement of actionable mutations in circulating tumor DNA
Cell Reports
October 7, 2021
IMM-1-104: a novel, oral, selective dual-MEK inhibitor that displays broad antitumor activity and high tolerability across RAS and RAF mutant tumors in vivo
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2021
October 7, 2021
Benchmarking the novel dual-MEK inhibitor, IMM-1-104, head-to-head and in combination with sotorasib (AMG-510) in the MIA PaCa-2 (KRAS-G12C) pancreatic cancer xenograft model
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2021
October 7, 2021
Transcriptional effects in C26 tumor highlight mechanistic aspects of a novel dual MEK inhibitor, IMM-1-104
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2021
October 4, 2021
Orchestrating and sharing large multimodal data for transparent and reproducible research
Nature Communications
September 9, 2021
Establishing community reference samples, data and call sets for benchmarking cancer mutation detection using whole-genome sequencing
Nature Biotechnology
September 9, 2021
Toward best practice in cancer mutation detection with whole-genome and whole-exome sequencing
Nature Biotechnology
June 3, 2021
Crowdsourced mapping of unexplored target space of kinase inhibitors
Nature Communications
April 30, 2021
Human transthyretin binding affinity of halogenated thiophenols and halogenated phenols: An in vitro and in silico study
Chemosphere
April 27, 2021
A primer on applying AI synergistically with domain expertise to oncology
Biochimica et Biophysica Acta (BBA) – Reviews on Cancer
April 16, 2021
A verified genomic reference sample for assessing performance of cancer panels detecting small variants of low allele frequency
Genome Biology
April 16, 2021
Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions
Genome Biology
April 12, 2021
Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology
Nature Biotechnology
October 14, 2020
Transparency and reproducibility in artificial intelligence
Nature
October 12, 2020
Clinical landscape of oncolytic virus research in 2020
Journal for ImmunoTherapy of Cancer
September 25, 2020
pS421 huntingtin modulates mitochondrial phenotypes and confers neuroprotection in an HD hiPSC model
Cell Death & Disease
August 13, 2020
Structures of Endocrine-Disrupting Chemicals Determine Binding to and Activation of the Estrogen Receptor α and Androgen Receptor
Environmental Science and Technology
June 25, 2020
Advanced bioinformatics rapidly identifies existing therapeutics for patients with coronavirus disease-2019 (COVID-19)
Journal of Translational Medicine
June 12, 2020
Quantitative Structure–Activity Relationship Models for Predicting Inflammatory Potential of Metal Oxide Nanoparticles
Environmental Health Perspectives
May 26, 2020
Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab
Leukemia
May 21, 2019
Advances in Computational Toxicology – Methodologies and Applications in Regulatory Science
Springer Nature Link
March 19, 2019
Realizing the promise of computational prediction in toxicology applications
Journal of Environmental Science and Health, Part C
March 19, 2019
Similarities and differences between variants called with human reference genome HG19 or HG38
BMC Bioinformatics
January 15, 2019
Computational prediction models for assessing endocrine disrupting potential of chemicals
Journal of Environmental Science and Health, Part C Environmental Carcinogenesis and Ecotoxicology Reviews
January 11, 2019
Computational prediction models for assessing endocrine disrupting potential of chemicals
Journal of Environmental Science and Health, Part C
May 30, 2018
Physicochemical, biological, functional and toxicological characterization of the European follow-on glatiramer acetate product as compared with Copaxone
eNeurologicalSci
May 21, 2018
Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse
Molecular Neurodegeneration
May 15, 2018
Structural Changes Due to Antagonist Binding in Ligand Binding Pocket of Androgen Receptor Elucidated through Molecular Dynamics Simulations
Frontiers in Pharmacology
April 18, 2018
Metastasis: Leveraging transcriptomics to identify potential therapeutics
American Association for Cancer Research Annual Meeting 2018
April 16, 2018
Cachexia: Leveraging transcriptomics to identify potential therapeutics
American Association for Cancer Research Annual Meeting 2018
April 9, 2018
Loss of the Sigma-1 receptor disrupts pridopidine-induced gene expression
Neurology
March 15, 2018
Integrity, standards, and QC-related issues with big-data in pre-clinical drug discovery
Biochemical Pharmacology
January 30, 2018
A meta-metastasis analysis identifies pan-cancer markers and therapeutic targets
Molecular Cancer Therapeutics
December 9, 2017
Cachexia mechanisms in cancer through the lens of transcriptomics
Society on Sarcopenia, Cachexia and Wasting Disorders 2017
December 8, 2017
The international MAQC Society launches to enhance reproducibility of high-throughput technologies
Nature Biotechnology
December 7, 2017
Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice
JCI Insight
December 7, 2017
Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice
JCI Insight
December 7, 2017
Proteomic Profiling Reveals Targetable Pathways in MGUS (SLAMF6, TNFRSF8, TIMP1, TRL2) That May Contribute to Disease Progression Blood 2017 130:3805;
Blood Journal
November 23, 2017
Compositional differences between Copaxone and Glatopa are reflected in altered immunomodulation ex vivo in a mouse model.
Annals of the New York Academy of Sciences
November 13, 2017
Transcriptomic analysis of the YAC128 HD mouse model shows disease mechanisms are ameliorated by pridopidine.
Neuroscience
May 31, 2017
A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis
Genome Medicine
May 18, 2017
Drug repurposing from the perspective of pharmaceutical companies
British Journal of Pharmacology
May 1, 2017
Pharmacogenomics strategies to optimize treatments for multiple sclerosis: Insights from clinical research.
Progress in Neurobiology
December 12, 2016
Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors
Cancer Cell
December 1, 2016
Daratumumab in Combination with Lenalidomide Plus Dexamethasone Induces Clonality Increase and T-Cell Expansion: Results from a Phase 3 Randomized Study (POLLUX)
Blood Journal
November 3, 2016
The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease
Neurobiology of Disease
October 25, 2016
Letter to the Editor response: Nygaard et al.
Biostatistics
October 19, 2016
Identifying transcriptomic mechanisms of gemcitabine resistance pathways in pancreatic cancer.
American Society of Human Genetics Annual Meeting 2016
September 26, 2016
Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor
Proceeding of the National Academy of Science
July 27, 2016
Pridopidine activates neuroprotective pathways impaired in Huntington Disease
Human Molecular Genetics
July 1, 2016
Abstract 789: Leveraging transcriptomic and genomic data to better select models for preclinical oncology therapeutic development to identify cell lines most similar to patient tumors
American Association for Cancer Research 2016
June 1, 2016
Similarities and differences in properties of glatiramer acetate (Copaxone®, Teva) versus polimunol (Synthon) using standard and emerging technologies: P11190
European Journal of Neurology
May 12, 2016
Biological Markers for Identifying Ibrutinib Resistance in Patients Having Mantle Cell Lymphoma and Methods of Using the Same
Patent Image
April 1, 2016
Leveraging transcriptomic and genomic data to better select models for preclinical oncology therapeutic development to identify cell lines most similar to patient tumors
American Society for Cancer Research 2016
February 1, 2016
Leveraging public genomic data to accelerate oncology therapeutic development in pancreatic cancer.
Advances in Genome Biology and Technology Annual Meeting 2016
December 3, 2015
Serum Proteomic Analysis of Multiple Myeloma Subjects Treated with Daratumumab Monotherapy
Blood Journal
November 24, 2015
Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition
Journal of Neuroimmunology
November 6, 2015
Accelerating pancreatic cancer drug screening by leveraging genomics to select better in vitro models
American Association for Cancer Research: International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications 2015
September 23, 2015
Leveraging existing data sets to generate new insights into Alzheimer’s disease biology in specific patient subsets
Scientific Reports
August 1, 2015
Improving pancreatic cancer drug discovery by leveraging genomics to select better in vitro models
American Association for Cancer Research Annual Meeting 2015
June 25, 2015
Glatiramoids
Non-Biological Complex Drugs
May 22, 2015
Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids
Scientific Reports
September 8, 2014
Use of genetic technologies to compare medicines
Clinical Genetics
May 22, 2014
Biomarkers for Predicting Clinical Response of Cancer Patients to Treatment with Immunotherapeutic Agent
Patent Image
January 8, 2014
Comparing the Biological Impact of Glatiramer Acetate with the Biological Impact of a Generic
PLoS One
March 26, 2013
Defining the Transcriptional and Cellular Landscape of Type 1 Diabetes in the NOD Mouse
PLoS One
January 2, 2012
Maximizing the efficacy of angiogenesis inhibitors
Journal of Clinical Oncology
December 5, 2011
IL-6 and ovarian cancer–letter
Clinical Cancer Research
June 12, 2009
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology
Journal of Translational Medicine